RS60181B1 - Terapeutska upotreba morfogenetskih proteina kosti - Google Patents

Terapeutska upotreba morfogenetskih proteina kosti

Info

Publication number
RS60181B1
RS60181B1 RS20200199A RSP20200199A RS60181B1 RS 60181 B1 RS60181 B1 RS 60181B1 RS 20200199 A RS20200199 A RS 20200199A RS P20200199 A RSP20200199 A RS P20200199A RS 60181 B1 RS60181 B1 RS 60181B1
Authority
RS
Serbia
Prior art keywords
therapeutic use
bone morphogenetic
morphogenetic proteins
proteins
bone
Prior art date
Application number
RS20200199A
Other languages
English (en)
Inventor
Nicholas W Morrell
Wei Li
Paul D Upton
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60181(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of RS60181B1 publication Critical patent/RS60181B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
RS20200199A 2014-07-10 2015-07-09 Terapeutska upotreba morfogenetskih proteina kosti RS60181B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1412290.7A GB201412290D0 (en) 2014-07-10 2014-07-10 Novel use
EP15739658.1A EP3166628B2 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins
PCT/GB2015/051989 WO2016005756A1 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins

Publications (1)

Publication Number Publication Date
RS60181B1 true RS60181B1 (sr) 2020-06-30

Family

ID=51453948

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20210631A RS61961B1 (sr) 2014-07-10 2015-07-09 Morfogenetski proteini kosti
RS20200199A RS60181B1 (sr) 2014-07-10 2015-07-09 Terapeutska upotreba morfogenetskih proteina kosti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20210631A RS61961B1 (sr) 2014-07-10 2015-07-09 Morfogenetski proteini kosti

Country Status (21)

Country Link
US (4) US10336800B2 (sr)
EP (3) EP3669886B1 (sr)
JP (1) JP6737770B2 (sr)
KR (2) KR20230049757A (sr)
CN (1) CN106661094B (sr)
AU (1) AU2015287397B2 (sr)
CA (1) CA2954221C (sr)
CY (2) CY1123011T1 (sr)
DK (2) DK3166628T3 (sr)
ES (2) ES2876124T3 (sr)
GB (1) GB201412290D0 (sr)
HR (2) HRP20200418T1 (sr)
HU (2) HUE048924T2 (sr)
LT (2) LT3669886T (sr)
MX (2) MX2017000448A (sr)
PL (2) PL3166628T5 (sr)
PT (2) PT3669886T (sr)
RS (2) RS61961B1 (sr)
RU (1) RU2733318C2 (sr)
SI (2) SI3669886T1 (sr)
WO (1) WO2016005756A1 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
EP3576776A4 (en) * 2017-02-06 2020-10-14 Acceleron Pharma Inc. COMPOSITIONS AND METHODS OF TREATMENT OF HEART DEFECTS
AU2018358804A1 (en) * 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
US20230285506A1 (en) * 2019-12-03 2023-09-14 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
WO2023012318A1 (en) * 2021-08-05 2023-02-09 Actelion Pharmaceuticals Ltd Bmp9 variant polypeptides and uses thereof
CN114317604B (zh) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 一种自发性肺动脉高压模型及构建方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171355A (en) * 1875-12-21 Improvement in driers
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
CA2108770C (en) * 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
JPH09501305A (ja) 1993-05-12 1997-02-10 ジェネティックス・インスティテュート・インコーポレイテッド Ｂｍｐ−１０組成物
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1996039431A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Bone morphogenic protein-10
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
WO2006130022A1 (en) 2005-05-30 2006-12-07 Agresearch Limited Modulation of ovulation by agonists and antagonists of bmprii
JP2009544325A (ja) 2006-07-27 2009-12-17 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
MX2009004718A (es) 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
WO2008151078A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
CA2718403A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2010114833A1 (en) 2009-04-01 2010-10-07 Indiana University Research And Technology Corporation Methods for treating diseases using a bone morphogenetic protein
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
EP3496739B1 (en) * 2016-07-15 2021-04-28 Acceleron Pharma Inc. Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
CN107760779B (zh) 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
BR112017000113A2 (pt) 2018-01-02
HRP20210734T1 (hr) 2021-06-11
PL3166628T5 (pl) 2023-11-27
US20170209540A1 (en) 2017-07-27
MX2017000448A (es) 2017-08-16
PT3166628T (pt) 2020-04-06
CY1123011T1 (el) 2021-10-29
JP2017521074A (ja) 2017-08-03
RS61961B1 (sr) 2021-07-30
US11572396B2 (en) 2023-02-07
EP3166628B1 (en) 2020-01-01
SI3669886T1 (sl) 2021-08-31
EP3166628A1 (en) 2017-05-17
WO2016005756A1 (en) 2016-01-14
EP3166628B2 (en) 2023-07-26
CN106661094B (zh) 2020-09-08
GB201412290D0 (en) 2014-08-27
HUE054512T2 (hu) 2021-09-28
HRP20200418T1 (hr) 2020-06-26
JP6737770B2 (ja) 2020-08-12
PL3166628T3 (pl) 2020-06-15
PL3669886T3 (pl) 2021-09-13
MX2020011333A (es) 2020-11-24
US20240043485A1 (en) 2024-02-08
LT3166628T (lt) 2020-04-10
US20170121383A1 (en) 2017-05-04
SI3166628T1 (sl) 2020-07-31
RU2733318C2 (ru) 2020-10-01
EP3906936A1 (en) 2021-11-10
ES2770073T3 (es) 2020-06-30
LT3669886T (lt) 2021-06-10
CA2954221A1 (en) 2016-01-14
KR20170029576A (ko) 2017-03-15
ES2770073T5 (es) 2024-03-04
CN106661094A (zh) 2017-05-10
KR102519869B1 (ko) 2023-04-07
DK3166628T3 (da) 2020-03-09
CA2954221C (en) 2023-02-14
KR20230049757A (ko) 2023-04-13
EP3669886B1 (en) 2021-02-24
AU2015287397A1 (en) 2017-02-16
ES2876124T3 (es) 2021-11-11
EP3669886A1 (en) 2020-06-24
RU2017102381A (ru) 2018-08-10
DK3669886T3 (da) 2021-05-25
AU2015287397B2 (en) 2020-08-20
HUE048924T2 (hu) 2020-09-28
CY1124143T1 (el) 2022-05-27
US20190359668A1 (en) 2019-11-28
US10336800B2 (en) 2019-07-02
PT3669886T (pt) 2021-05-25
RU2017102381A3 (sr) 2019-02-28

Similar Documents

Publication Publication Date Title
PL3166628T3 (pl) Zastosowanie lecznicze białek morfogenetycznych kości
HK1256356A1 (zh) 用於誘導組織形成的化合物及其用途
HK1249865B (zh) 疼痛的治療
HK1256358A1 (zh) 用於誘導組織形成的化合物及其用途
IL277377B (en) Prohemostatic proteins for the treatment of bleeding
HK1257488A1 (zh) 骨形成
IL286670B (en) Compounds for inducing tissue formation and their uses
HK1256243A1 (zh) 誘導組織形成的化合物及其應用
GB201504413D0 (en) Treatment of disease
TWM489058U (en) Structure of medical tweezers
GB201414023D0 (en) Treatment of autoimmune diseases